Press Releases :: Sonnet BioTherapeutics, Inc. (PURR)

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Trading on The Nasdaq Capital Market under the ticker symbol “PURR”

Full Press Release Here

Sep 26, 2022 8:00am EDT

Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee

Sep 21, 2022 8:00am EDT

Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010

Sep 16, 2022 8:30am EDT

Sonnet BioTherapeutics Announces 1-for-14 Reverse Stock Split

Aug 15, 2022 4:05pm EDT

Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Business and Earnings Update

Jul 22, 2022 7:00am EDT

Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy

Jul 21, 2022 7:30am EDT

Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers

Jun 09, 2022 7:00am EDT

Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition

Jun 02, 2022 9:25am EDT

Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum

May 10, 2022 8:15am EDT

Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update

Apr 13, 2022 7:00am EDT

Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors

1...
4
5
6
7
8
9
10
11
12
13